Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Fig. 3

Association between trough plasma ozoralizumab concentration and ACR20 response at week 16. The 16-week ACR20 response rates were compared by quartile in the OHZORA trial (A) and the NATSUZORA trial (B), or stratified as above and below the boundary value, which was 1.15 µg/mL in the OHZORA trial (C) and 1.00 µg/mL in the NATSUZORA trial (D). Fisher’s exact test, *p < 0.05, **p < 0.01. ACR20 ≥ 20% improvement according to the American College of Rheumatology criteria, n.s. not significant

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us